» Articles » PMID: 23977201

Rotenone Directly Induces BV2 Cell Activation Via the P38 MAPK Pathway

Overview
Journal PLoS One
Date 2013 Aug 27
PMID 23977201
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disease. Although its pathogenesis is still unclear, increasing evidence suggests that mitochondrial dysfunction induced by environmental toxins, such as mitochondrial complex I inhibitors, plays a significant role in the disease process. The microglia in PD brains are highly activated, and inflammation is also an essential element in PD pathogenesis. However, the means by which these toxins activate microglia is still unclear. In the present study, we found that rotenone, a mitochondrial complex I inhibitor, could directly activate microglia via the nuclear factor kappa B (NF-κB) signaling pathway, thereby inducing significantly increased expression of inflammatory cytokines. We further observed that rotenone induced caspase-1 activation and mature IL-1β release, both of which are strictly dependent on p38 mitogen-activated protein kinase (MAPK). The activation of p38 is associated with the presence of reactive oxygen species (ROS) produced by rotenone. Removal of these ROS abrogated the activation of the microglia. Therefore, our data suggest that the environmental toxin rotenone can directly activate microglia through the p38 MAPK pathway.

Citing Articles

The effect of AKT inhibition in α-synuclein-dependent neurodegeneration.

Ranxhi B, Bangash Z, Chbihi Z, Todi S, LeWitt P, Tsou W Front Mol Neurosci. 2025; 18:1524044.

PMID: 39974188 PMC: 11835820. DOI: 10.3389/fnmol.2025.1524044.


Microglia: roles and genetic risk in Parkinson's disease.

Trainor A, MacDonald D, Penney J Front Neurosci. 2024; 18:1506358.

PMID: 39554849 PMC: 11564156. DOI: 10.3389/fnins.2024.1506358.


Orexin B protects dopaminergic neurons from 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity associated with reduced extracellular signal-regulated kinase phosphorylation.

Ma X, Cao F, Cui J, Li X, Yin Z, Wu Y Mol Biol Rep. 2024; 51(1):669.

PMID: 38787465 DOI: 10.1007/s11033-024-09587-2.


What Can Inflammation Tell Us about Therapeutic Strategies for Parkinson's Disease?.

Xue J, Tao K, Wang W, Wang X Int J Mol Sci. 2024; 25(3).

PMID: 38338925 PMC: 10855787. DOI: 10.3390/ijms25031641.


3-N-butylphthalide attenuates neuroinflammation in rotenone-induced Parkinson's disease models via the cGAS-STING pathway.

Liu Y, Duan R, Li P, Zhang B, Liu Y Int J Immunopathol Pharmacol. 2024; 38:3946320241229041.

PMID: 38315064 PMC: 10846052. DOI: 10.1177/03946320241229041.


References
1.
ENGLAND Jr A, SCHWAB R . Parkinson's syndrome. N Engl J Med. 1961; 265:837-44 concl. DOI: 10.1056/NEJM196110262651706. View

2.
Dawson T, Dawson V . Molecular pathways of neurodegeneration in Parkinson's disease. Science. 2003; 302(5646):819-22. DOI: 10.1126/science.1087753. View

3.
Abou-Sleiman P, Muqit M, Wood N . Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci. 2006; 7(3):207-19. DOI: 10.1038/nrn1868. View

4.
Lucin K, Wyss-Coray T . Immune activation in brain aging and neurodegeneration: too much or too little?. Neuron. 2009; 64(1):110-22. PMC: 2834890. DOI: 10.1016/j.neuron.2009.08.039. View

5.
Wada R, Tifft C, Proia R . Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc Natl Acad Sci U S A. 2000; 97(20):10954-9. PMC: 27130. DOI: 10.1073/pnas.97.20.10954. View